Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| FILANA THERAPEUTICS, INC.SAVA · Entity 7294 | Director | May 23, 2025 | May 27, 2025 |
| PTC THERAPEUTICS, INC.PTCT · Entity 3803 | CHIEF FINANCIAL OFFICER | July 14, 2026 | July 16, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
FILANA THERAPEUTICS, INC.
Report date May 23, 2025 · Filed May 27, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.11 · Expires 2035-05-23 | Direct | 26,500 |
Reported balance
After 2025-05-23 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-05-23 · Grant · Acquired 26,500 · Balance 26,500 F1: Form 4 represents grant pursuant to the Amended Non-employee Director Compensation Program approved by stockholders on May 23, 2025. Stock options vest over a one (1) year period at a rate of 1/12 per month. |
Filing footnotes · ownership attribution and instrument terms
F1: Form 4 represents grant pursuant to the Amended Non-employee Director Compensation Program approved by stockholders on May 23, 2025. Stock options vest over a one (1) year period at a rate of 1/12 per month.
PTC THERAPEUTICS, INC.
Report date July 14, 2026 · Filed July 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 83,986 |
Reported balance
After 2026-07-14 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-07-14 · Sale · Disposed 3,494 · Balance 83,986 F1: Represents shares automatically sold pursuant to an irrevocable sell to cover election entered into upon acceptance of the grant to satisfy tax withholding obligations in connection with the vesting of 6,500 RSUs from a July 13, 2023 grant of 26,000 RSUs F2: Includes 162 shares of common stock acquired under the Issuer's employee stock purchase plan for the period ended June 30, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares automatically sold pursuant to an irrevocable sell to cover election entered into upon acceptance of the grant to satisfy tax withholding obligations in connection with the vesting of 6,500 RSUs from a July 13, 2023 grant of 26,000 RSUs
F2: Includes 162 shares of common stock acquired under the Issuer's employee stock purchase plan for the period ended June 30, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 14, 2026 Filed Jul 16, 2026 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 3,494 | $80.35 | $280,742.90 |
DisclosureSEC source: 0001984065-26-000008 · form4-07162026_050701.xml · nonDerivative · entry 1 Gravier Pierre · CIK 0001984065 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 83,986 F1 · kind: Represents shares automatically sold pursuant to an irrevocable sell to cover election entered into upon acceptance of the grant to satisfy tax withholding obligations in connection with the vesting of 6,500 RSUs from a July 13, 2023 grant of 26,000 RSUs F2 · balance_after: Includes 162 shares of common stock acquired under the Issuer's employee stock purchase plan for the period ended June 30, 2026. Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 2,992 | $69.36 | $207,525.12 |
DisclosureSEC source: 0001984065-26-000006 · form4-02202026_050209.xml · nonDerivative · entry 1 Gravier Pierre · CIK 0001984065 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 87,318 F1 · shares: Represents shares automatically sold pursuant to an irrevocable sell to cover election entered into upon acceptance of the grant to satisfy tax withholding obligations in connection with the vesting of 4,750 RSUs from a February 15, 2024 grant of 19,000 RSUs and the vesting of 1,550 RSUs from a February 15, 2024 grant of 3,100 RSUs. Read SEC document |
| January 06, 2026 Filed Jan 8, 2026 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 2,139 | $76.95 | $164,596.05 |
DisclosureSEC source: 0001984065-26-000004 · form4-01082026_050121.xml · nonDerivative · entry 1 Gravier Pierre · CIK 0001984065 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 90,310 F1 · shares: Represents shares automatically sold pursuant to an irrevocable sell to cover election entered into upon acceptance of the grant to satisfy tax withholding obligations in connection with the vesting of 5,625 RSUs from a January 3, 2025 grant of 22,500 RSUs Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $76.74 | $0.00 |
DisclosureSEC source: 0001984065-26-000002 · form4-01062026_050105.xml · derivative · entry 2 Gravier Pierre · CIK 0001984065 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2036-01-01 F3 · derivative.exercise_date: This option was granted on January 2, 2026, and vests over four years, with 25% of the shares underlying the option vesting on January 2, 2027, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 2, 2027. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001984065-26-000002 · form4-01062026_050105.xml · nonDerivative · entry 1 Gravier Pierre · CIK 0001984065 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 92,449 F1 · shares: Restricted stock units granted on January 2, 2026 that vest in four equal installments over four years, commencing on January 2, 2027. F2 · balance_after: Includes 272 shares of common stock acquired under the Issuer's employee stock purchase plan for the period ended June 30, 2025, and 257 shares of common stock acquired under the Issuer's employee stock purchase plan for the period ended December 31, 2025. Read SEC document |
| July 15, 2025 Filed Jul 17, 2025 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 2,516 | $49.46 | $124,441.36 |
DisclosureSEC source: 0001415889-25-019964 · form4-07172025_050701.xml · nonDerivative · entry 1 Gravier Pierre · CIK 0001984065 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 71,920 F1 · shares: Represents shares automatically sold pursuant to an irrevocable sell to cover election entered into upon acceptance of the grant to satisfy tax withholding obligations in connection with the vesting of 6,500 RSUs from a July 13, 2023 grant of 26,000 RSUs Read SEC document |
| May 23, 2025 Filed May 27, 2025 20:23 UTC | FILANA THERAPEUTICS, INC. SAVA · Entity 7294 | GrantStock Option (Right to Buy) · Derivative | 26,500 | $0.00 Strike: $2.11 | $0.00 |
DisclosureSEC source: 0001437749-25-018503 · rdgdoc.xml · derivative · entry 1 Gravier Pierre · CIK 0001984065 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,500 Underlying: Common Stock · 26,500 shares Expires 2035-05-23 F1 · derivative.exercise_date: Form 4 represents grant pursuant to the Amended Non-employee Director Compensation Program approved by stockholders on May 23, 2025. Stock options vest over a one (1) year period at a rate of 1/12 per month. Read SEC document |
| February 20, 2025 Filed Feb 21, 2025 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 1,167 | $50.12 | $58,494.71 |
DisclosureSEC source: 0001415889-25-005138 · form4-02212025_050213.xml · nonDerivative · entry 2 Gravier Pierre · CIK 0001984065 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 74,436 F1 · shares: Represents shares automatically sold pursuant to an irrevocable sell to cover election entered into upon acceptance of the grant to satisfy tax withholding obligations in connection with the vesting of 4,750 RSUs from a February 15, 2024 grant of 19,000 RSUs and the vesting of 1,550 RSUs from a February 15, 2024 grant of 3,100 RSUs. Read SEC document |
| February 19, 2025 Filed Feb 21, 2025 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 1,168 | $50.10 | $58,512.13 |
DisclosureSEC source: 0001415889-25-005138 · form4-02212025_050213.xml · nonDerivative · entry 1 Gravier Pierre · CIK 0001984065 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 75,603 F1 · shares: Represents shares automatically sold pursuant to an irrevocable sell to cover election entered into upon acceptance of the grant to satisfy tax withholding obligations in connection with the vesting of 4,750 RSUs from a February 15, 2024 grant of 19,000 RSUs and the vesting of 1,550 RSUs from a February 15, 2024 grant of 3,100 RSUs. Read SEC document |
| January 03, 2025 Filed Jan 7, 2025 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantStock Option (Right to Buy) · Derivative | 56,250 | $0.00 Strike: $46.54 | $0.00 |
DisclosureSEC source: 0001415889-25-001016 · form4-01072025_050103.xml · derivative · entry 2 Gravier Pierre · CIK 0001984065 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,250 Underlying: Common Stock · 56,250 shares Expires 2035-01-02 F3 · derivative.exercise_date: This option was granted on January 3, 2025, and vests over four years, with 25% of the shares underlying the option vesting on January 3, 2026, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 3, 2026. Read SEC document |
| January 03, 2025 Filed Jan 7, 2025 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantCommon Stock | 22,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-001016 · form4-01072025_050103.xml · nonDerivative · entry 1 Gravier Pierre · CIK 0001984065 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 76,771 F1 · price: Restricted stock units granted on January 3, 2025 that vest in four equal installments over four years, commencing on January 3, 2026. F2 · balance_after: Includes 339 shares of common stock acquired under the Issuer's employee stock purchase plan for the period ended June 30, 2024, and 401 shares of common stock acquired under the Issuer's employee stock purchase plan for the period ended December 31, 2024. Read SEC document |
| July 16, 2024 Filed Jul 18, 2024 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 2,269 | $34.02 | $77,200.46 |
DisclosureSEC source: 0001415889-24-019773 · form4-07182024_050701.xml · nonDerivative · entry 1 Gravier Pierre · CIK 0001984065 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 53,531 F1 · shares: Represents shares automatically sold pursuant to an irrevocable sell to cover election entered into upon acceptance of the grant to satisfy tax withholding obligations in connection with the vesting of 6,500 RSUs from a July 13, 2023 grant of 26,000 RSUs. Read SEC document |
| May 09, 2024 Filed May 13, 2024 20:11 UTC | FILANA THERAPEUTICS, INC. SAVA · Entity 7294 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $21.11 | $0.00 |
DisclosureSEC source: 0001437749-24-016237 · rdgdoc.xml · derivative · entry 1 Gravier Pierre · CIK 0001984065 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2034-05-09 F1 · derivative.exercise_date: Form 4 represents grant pursuant to the Non-employee Director Compensation Program approved by stockholders on May 4, 2023. Stock options vest over a one (1) year period at a rate of 1/12 per month. Read SEC document |
| February 15, 2024 Filed Feb 16, 2024 21:11 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantStock Option (Right to Buy) · Derivative | 47,500 | $0.00 Strike: $25.69 | $0.00 |
DisclosureSEC source: 0001415889-24-004108 · form4-02162024_040248.xml · derivative · entry 3 Gravier Pierre · CIK 0001984065 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,500 Underlying: Common Stock · 47,500 shares Expires 2034-02-14 F3 · derivative.exercise_date: This option was granted on February 15, 2024, and vests over four years, with 25% of the shares underlying the option vesting on February 15, 2025, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on May 15, 2025. Read SEC document |
| February 15, 2024 Filed Feb 16, 2024 21:11 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantCommon Stock | 3,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-004108 · form4-02162024_040248.xml · nonDerivative · entry 2 Gravier Pierre · CIK 0001984065 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,800 F2 · shares: Restricted stock units granted on February 15, 2024 that vest in two equal installments over two years, commencing on February 15, 2025. Read SEC document |
| February 15, 2024 Filed Feb 16, 2024 21:11 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantCommon Stock | 19,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-004108 · form4-02162024_040248.xml · nonDerivative · entry 1 Gravier Pierre · CIK 0001984065 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,700 F1 · shares: Restricted stock units granted on February 15, 2024 that vest in four equal installments over four years, commencing on February 15, 2025. Read SEC document |
| December 12, 2023 Filed Dec 14, 2023 21:38 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | PurchaseCommon Stock | 7,700 | $25.81 | $198,736.23 |
DisclosureSEC source: 0001415889-23-016478 · form4-12142023_091224.xml · nonDerivative · entry 1 Gravier Pierre · CIK 0001984065 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,700 F1 · price: This price represents the weighted average price of purchase transactions that were executed in multiple trades at prices ranging from $25.77 to $25.82 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| December 06, 2023 Filed Dec 7, 2023 21:57 UTC | FILANA THERAPEUTICS, INC. SAVA · Entity 7294 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $21.71 | $0.00 |
DisclosureSEC source: 0001437749-23-033892 · rdgdoc.xml · derivative · entry 1 Gravier Pierre · CIK 0001984065 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2033-12-06 F1 · derivative.exercise_date: The stock option vests over three (3) years at a rate of 1/36th each month. Read SEC document |
| July 13, 2023 Filed Jul 17, 2023 20:51 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantStock Option (Right to Buy) · Derivative | 65,000 | $0.00 Strike: $39.82 | $0.00 |
DisclosureSEC source: 0001415889-23-011167 · form4-07172023_080747.xml · derivative · entry 2 Gravier Pierre · CIK 0001984065 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2033-07-12 F2 · derivative.exercise_date: This option was granted on July 13, 2023, and vests over four years, with 25% of the shares underlying the option vesting on July 13, 2024, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on October 13, 2024. Read SEC document |
| July 13, 2023 Filed Jul 17, 2023 20:51 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantCommon Stock | 26,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-011167 · form4-07172023_080747.xml · nonDerivative · entry 1 Gravier Pierre · CIK 0001984065 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,000 F1 · shares: Restricted stock units granted on July 13, 2023 that vest in four equal installments over four years, commencing on July 13, 2024. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.